Source: Annual Congress 2011 - Respiratory epidemiology: quality of life, therapy and socioeconomics
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Laforest, J. Martin, I. Licaj, G. Devouassoux, G. Chatte, M. Broquet, E. Van Ganse (Lyon, Pierre Benite, Caluire, France). Correlates of high levels of use of short-acting beta agonists in asthma. Eur Respir J 2011; 38: Suppl. 55, 4122

Member's Comments

No comment yet.

Related content which might interest you: Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Is there a problem with short-acting beta-2 agonist monotherapy in asthma? Source: Virtual Congress 2020 – Airway diseases Year: 2020 What predicts short-acting beta agonist (SABA) monotherapy use in children? Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Polymorphism of β2-adrenergic receptor (β2-AR) and regular use of long-acting β-agonists in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007 High use of SABAs is associated with higher exacerbation frequency Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001 Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001 Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Use of multifactor-dimensionality reduction model predicting bronchodilator response by inhaled short-acting beta 2 agonist Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review Source: Annual Congress 2011 - Asthma management and response Year: 2011 Combination of beta2 agonists and anticholinergic drugs improves lung function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 726s Year: 2006 Use of partition tree to Identify genetic marker combination predicting bronchodilator response by inhaled short-acting beta 2 agonist Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011 Interaction between the Arg16 homozygous genotype, inhaled corticosteroids and long acting beta agonists for asthma exacerbations in children? Leukotriene receptor antagonists to the rescue? Source: Annual Congress 2013 –Asthma and lung development: from genes to environment Year: 2013 Abediterol, a novel long-acting inhaled beta2-agonist, has a fast association rate and long residence time at human beta2 receptors Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Effect of long-acting muscarinic antagonist (LAMA) on 24-hour physical behaviours in COPD Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation Year: 2020 Long-acting β2-agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004